Please use this identifier to cite or link to this item:
|Scopus||Web of Science®||Altmetric|
|Title:||ABCA transporter gene expression and poor outcome in epithelial ovarian cancer|
Australian Ovarian Cancer Study Group
|Citation:||Journal of the National Cancer Institute, 2014; 106(7):dju149-1-dju149-11|
|Publisher:||Oxford University Press|
|Ellen L. Hedditch, Bo Gao, Amanda J. Russell, Yi Lu, Catherine Emmanuel, Jonathan Beesley ... et al.|
|Abstract:||Background: ATP-binding cassette (ABC) transporters play various roles in cancer biology and drug resistance, but their association with outcomes in serous epithelial ovarian cancer (EOC) is unknown. Methods: The relationship between clinical outcomes and ABC transporter gene expression in two independent cohorts of high-grade serous EOC tumors was assessed with real-time quantitative polymerase chain reaction, analysis of expression microarray data, and immunohistochemistry. Associations between clinical outcomes and ABCA transporter gene single nucleotide polymorphisms were tested in a genome-wide association study. Impact of short interfering RNA–mediated gene suppression was determined by colony forming and migration assays. Association with survival was assessed with Kaplan–Meier analysis and log-rank tests. All statistical tests were two-sided. Results: Associations with outcome were observed with ABC transporters of the “A” subfamily, but not with multidrug transporters. High-level expression of ABCA1, ABCA6, ABCA8, and ABCA9 in primary tumors was statistically significantly associated with reduced survival in serous ovarian cancer patients. Low levels of ABCA5 and the C-allele of rs536009 were associated with shorter overall survival (hazard ratio for death = 1.50; 95% confidence interval [CI] =1.26 to 1.79; P = 6.5e−6). The combined expression pattern of ABCA1, ABCA5, and either ABCA8 or ABCA9 was associated with particularly poor outcome (mean overall survival in group with adverse ABCA1, ABCA5 and ABCA9 gene expression = 33.2 months, 95% CI = 26.4 to 40.1; vs 55.3 months in the group with favorable ABCA gene expression, 95% CI = 49.8 to 60.8; P = .001), independently of tumor stage or surgical debulking status. Suppression of cholesterol transporter ABCA1 inhibited ovarian cancer cell growth and migration in vitro, and statin treatment reduced ovarian cancer cell migration. Conclusions: Expression of ABCA transporters was associated with poor outcome in serous ovarian cancer, implicating lipid trafficking as a potentially important process in EOC.|
|Keywords:||Statins; gene expression; immunohistochemistry; cell growth; cholesterol; debulking; atp-binding cassette transporters; cell motility; genes; membrane transport proteins; single nucleotide polymorphism; surgical procedures; operative; lipids; neoplasms; treatment outcome; ovarian cancer; rna; carcinoma, ovarian epithelial, abca1 gene; genome-wide association study; quantitative real-time polymerase chain reaction|
|Description:||Martin K. Oehler is a member of the Australian Ovarian Cancer Study Group|
|Rights:||© The Author 2014. Published by Oxford University Press. All rights reserved. For Permissions, please e-mail: firstname.lastname@example.org.|
|Appears in Collections:||Aurora harvest 7|
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.